{"paper_id": "e4a776f7ef5ec5d2326a78544948649dd74c384d", "metadata": {"title": "Protocol", "authors": []}, "abstract": [{"text": "This document contains: -The original protocol document (v1.0) -The final protocol document (v2.0) -A summary of changes between protocol version 1.0 and 2.0 -The statistical analysis plan (unchanged from original version) c X X X X X X X X 7 X", "cite_spans": [], "ref_spans": [], "section": "Abstract"}], "body_text": [{"text": "A randomized, open-label study to evaluate the efficacy and safety of lopinavir-ritonavir and interferon-\u03b1 in hospitalized patients with novel Table 1 : Baseline characteristics -ITT population. Table 2 : Outcomes in the intention-to-treat population. Table 3 : Outcomes in the modified intention-to-treat population. ", "cite_spans": [], "ref_spans": [{"start": 143, "end": 150, "text": "Table 1", "ref_id": null}, {"start": 195, "end": 202, "text": "Table 2", "ref_id": "TABREF5"}, {"start": 252, "end": 259, "text": "Table 3", "ref_id": "TABREF6"}], "section": "/ -\u03b12b"}, {"text": "China-Japan Friendship Jin Yin Tan Hospital Differences were expressed as rate differences or Hodges-Lehmann estimator and 95% confidence intervals. \u2020 The hazard ratio was estimated by COX proportional risk model. Differences were expressed as rate differences or Hodges-Lehmann estimator and 95% confidence intervals. \u2020 The hazard ratio was estimated by COX proportional risk model. Denominator of the percentage is the total number of patients in each group. Denominator of the percentage is the total number of patients in the each group.", "cite_spans": [], "ref_spans": [], "section": "Center Names"}], "bib_entries": {"BIBREF0": {"ref_id": "b0", "title": "A Novel Coronavirus Associated with Severe Acute Respiratory Syndrome", "authors": [{"first": "T", "middle": ["G"], "last": "Ksiazek", "suffix": ""}, {"first": "D", "middle": [], "last": "Erdman", "suffix": ""}, {"first": "C", "middle": ["S"], "last": "Goldsmith", "suffix": ""}], "year": 2003, "venue": "N Engl J Med", "volume": "348", "issn": "", "pages": "1953--66", "other_ids": {}}, "BIBREF1": {"ref_id": "b1", "title": "Identification of a Novel Coronavirus in Patients with Severe Acute Respiratory Syndrome", "authors": [{"first": "C", "middle": [], "last": "Drosten", "suffix": ""}, {"first": "S", "middle": [], "last": "G\u00fcnther", "suffix": ""}, {"first": "W", "middle": [], "last": "Preiser", "suffix": ""}], "year": 2003, "venue": "N Engl J Med", "volume": "348", "issn": "", "pages": "1967--76", "other_ids": {}}, "BIBREF2": {"ref_id": "b2", "title": "Middle East Respiratory Syndrome: Emergence of a Pathogenic Human Coronavirus", "authors": [{"first": "A", "middle": ["R"], "last": "Fehr", "suffix": ""}, {"first": "R", "middle": [], "last": "Channappanavar", "suffix": ""}, {"first": "S", "middle": [], "last": "Perlman", "suffix": ""}], "year": 2017, "venue": "Annu Rev Med", "volume": "68", "issn": "", "pages": "387--99", "other_ids": {}}, "BIBREF3": {"ref_id": "b3", "title": "Treatment with interferon-\u03b12b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques", "authors": [{"first": "D", "middle": [], "last": "Falzarano", "suffix": ""}, {"first": "E", "middle": [], "last": "De Wit", "suffix": ""}, {"first": "A", "middle": ["L"], "last": "Rasmussen", "suffix": ""}], "year": 2013, "venue": "Nat Med", "volume": "19", "issn": "", "pages": "1313--1320", "other_ids": {}}, "BIBREF4": {"ref_id": "b4", "title": "Combination therapy with lopinavir/ritonavir, ribavirin and interferon-alpha for Middle East respiratory syndrome: a case report", "authors": [{"first": "U", "middle": ["J"], "last": "Kim", "suffix": ""}, {"first": "E-J", "middle": [], "last": "Won", "suffix": ""}, {"first": "S-J", "middle": [], "last": "Kee", "suffix": ""}, {"first": "Jung S-I", "middle": [], "last": "Jang", "suffix": ""}, {"first": "H-C", "middle": [], "last": "", "suffix": ""}], "year": 2015, "venue": "Antivir Ther", "volume": "21", "issn": "", "pages": "455--464", "other_ids": {}}, "BIBREF5": {"ref_id": "b5", "title": "Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus", "authors": [{"first": "Jfw", "middle": [], "last": "Chan", "suffix": ""}, {"first": "K-H", "middle": [], "last": "Chan", "suffix": ""}, {"first": "Ryt", "middle": [], "last": "Kao", "suffix": ""}], "year": 2013, "venue": "J Infect", "volume": "67", "issn": "", "pages": "606--622", "other_ids": {}}, "BIBREF6": {"ref_id": "b6", "title": "IFN-\u03b12a or IFN-\u03b21a in combination with ribavirin to treat Middle East respiratory syndrome coronavirus pneumonia: a retrospective study", "authors": [{"first": "S", "middle": [], "last": "Shalhoub", "suffix": ""}, {"first": "F", "middle": [], "last": "Farahat", "suffix": ""}, {"first": "Al-Jiffri A", "middle": [], "last": "", "suffix": ""}], "year": 2015, "venue": "J Antimicrob Chemother", "volume": "70", "issn": "", "pages": "2129--2161", "other_ids": {}}, "BIBREF7": {"ref_id": "b7", "title": "Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: an observational study", "authors": [{"first": "J", "middle": ["A"], "last": "Al-Tawfiq", "suffix": ""}, {"first": "H", "middle": [], "last": "Momattin", "suffix": ""}, {"first": "J", "middle": [], "last": "Dib", "suffix": ""}, {"first": "Z", "middle": ["A"], "last": "Memish", "suffix": ""}], "year": 2014, "venue": "Int J Infect Dis IJID Off Publ Int Soc Infect Dis", "volume": "20", "issn": "", "pages": "42--48", "other_ids": {}}, "BIBREF8": {"ref_id": "b8", "title": "Efficacy and biological safety of lopinavir/ritonavir based anti-retroviral therapy in HIV-1-infected patients: a meta-analysis of randomized controlled trials", "authors": [{"first": "X", "middle": [], "last": "Huang", "suffix": ""}, {"first": "Y", "middle": [], "last": "Xu", "suffix": ""}, {"first": "Q", "middle": [], "last": "Yang", "suffix": ""}], "year": 2015, "venue": "Sci Rep", "volume": "5", "issn": "", "pages": "", "other_ids": {}}, "BIBREF9": {"ref_id": "b9", "title": "Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings", "authors": [{"first": "C", "middle": ["M"], "last": "Chu", "suffix": ""}], "year": 2004, "venue": "Thorax", "volume": "59", "issn": "", "pages": "252--258", "other_ids": {}}, "BIBREF10": {"ref_id": "b10", "title": "Virological and serological analysis of a recent Middle East respiratory syndrome coronavirus infection case on a triple combination antiviral regimen", "authors": [{"first": "N", "middle": [], "last": "Spanakis", "suffix": ""}, {"first": "S", "middle": [], "last": "Tsiodras", "suffix": ""}, {"first": "B", "middle": ["L"], "last": "Haagmans", "suffix": ""}], "year": 2014, "venue": "Int J Antimicrob Agents", "volume": "44", "issn": "", "pages": "528--560", "other_ids": {}}, "BIBREF11": {"ref_id": "b11", "title": "Comparative and kinetic analysis of viral shedding and immunological responses in MERS patients representing a broad spectrum of disease severity", "authors": [{"first": "C-K", "middle": [], "last": "Min", "suffix": ""}, {"first": "S", "middle": [], "last": "Cheon", "suffix": ""}, {"first": "N-Y", "middle": [], "last": "Ha", "suffix": ""}], "year": 2016, "venue": "Sci Rep", "volume": "6", "issn": "", "pages": "", "other_ids": {}}, "BIBREF12": {"ref_id": "b12", "title": "A Novel Coronavirus Associated with Severe Acute Respiratory Syndrome", "authors": [{"first": "T", "middle": ["G"], "last": "Ksiazek", "suffix": ""}, {"first": "D", "middle": [], "last": "Erdman", "suffix": ""}, {"first": "C", "middle": ["S"], "last": "Goldsmith", "suffix": ""}], "year": 2003, "venue": "N Engl J Med", "volume": "348", "issn": "", "pages": "1953--66", "other_ids": {}}, "BIBREF13": {"ref_id": "b13", "title": "Identification of a Novel Coronavirus in Patients with Severe Acute Respiratory Syndrome", "authors": [{"first": "C", "middle": [], "last": "Drosten", "suffix": ""}, {"first": "S", "middle": [], "last": "G\u00fcnther", "suffix": ""}, {"first": "W", "middle": [], "last": "Preiser", "suffix": ""}], "year": 2003, "venue": "N Engl J Med", "volume": "348", "issn": "", "pages": "1967--76", "other_ids": {}}, "BIBREF14": {"ref_id": "b14", "title": "Middle East Respiratory Syndrome: Emergence of a Pathogenic Human Coronavirus", "authors": [{"first": "A", "middle": ["R"], "last": "Fehr", "suffix": ""}, {"first": "R", "middle": [], "last": "Channappanavar", "suffix": ""}, {"first": "S", "middle": [], "last": "Perlman", "suffix": ""}], "year": 2017, "venue": "Annu Rev Med", "volume": "68", "issn": "", "pages": "387--99", "other_ids": {}}, "BIBREF15": {"ref_id": "b15", "title": "Treatment with interferon-\u03b12b and ribavirin improves 78 outcome in MERS-CoV-infected rhesus macaques", "authors": [{"first": "D", "middle": [], "last": "Falzarano", "suffix": ""}, {"first": "E", "middle": [], "last": "De Wit", "suffix": ""}, {"first": "A", "middle": ["L"], "last": "Rasmussen", "suffix": ""}], "year": 2013, "venue": "Nat Med", "volume": "19", "issn": "", "pages": "1313--1320", "other_ids": {}}, "BIBREF16": {"ref_id": "b16", "title": "Combination therapy with lopinavir/ritonavir, ribavirin and interferon-alpha for Middle East respiratory syndrome: a case report", "authors": [{"first": "U", "middle": ["J"], "last": "Kim", "suffix": ""}, {"first": "E-J", "middle": [], "last": "Won", "suffix": ""}, {"first": "S-J", "middle": [], "last": "Kee", "suffix": ""}, {"first": "Jung S-I", "middle": [], "last": "Jang", "suffix": ""}, {"first": "H-C", "middle": [], "last": "", "suffix": ""}], "year": 2015, "venue": "Antivir Ther", "volume": "21", "issn": "", "pages": "455--464", "other_ids": {}}, "BIBREF17": {"ref_id": "b17", "title": "Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus", "authors": [{"first": "Jfw", "middle": [], "last": "Chan", "suffix": ""}, {"first": "K-H", "middle": [], "last": "Chan", "suffix": ""}, {"first": "Ryt", "middle": [], "last": "Kao", "suffix": ""}], "year": 2013, "venue": "J Infect", "volume": "67", "issn": "", "pages": "606--622", "other_ids": {}}, "BIBREF18": {"ref_id": "b18", "title": "IFN-\u03b12a or IFN-\u03b21a in combination with ribavirin to treat Middle East respiratory syndrome coronavirus pneumonia: a retrospective study", "authors": [{"first": "S", "middle": [], "last": "Shalhoub", "suffix": ""}, {"first": "F", "middle": [], "last": "Farahat", "suffix": ""}, {"first": "Al-Jiffri A", "middle": [], "last": "", "suffix": ""}], "year": 2015, "venue": "J Antimicrob Chemother", "volume": "70", "issn": "", "pages": "2129--2161", "other_ids": {}}, "BIBREF19": {"ref_id": "b19", "title": "Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: an observational study", "authors": [{"first": "J", "middle": ["A"], "last": "Al-Tawfiq", "suffix": ""}, {"first": "H", "middle": [], "last": "Momattin", "suffix": ""}, {"first": "J", "middle": [], "last": "Dib", "suffix": ""}, {"first": "Z", "middle": ["A"], "last": "Memish", "suffix": ""}], "year": 2014, "venue": "Int J Infect Dis IJID Off Publ Int Soc Infect Dis", "volume": "20", "issn": "", "pages": "42--48", "other_ids": {}}, "BIBREF20": {"ref_id": "b20", "title": "Efficacy and biological safety of lopinavir/ritonavir based anti-retroviral therapy in HIV-1-infected patients: a meta-analysis of randomized controlled trials", "authors": [{"first": "X", "middle": [], "last": "Huang", "suffix": ""}, {"first": "Y", "middle": [], "last": "Xu", "suffix": ""}, {"first": "Q", "middle": [], "last": "Yang", "suffix": ""}], "year": 2015, "venue": "Sci Rep", "volume": "5", "issn": "", "pages": "", "other_ids": {}}, "BIBREF21": {"ref_id": "b21", "title": "Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings", "authors": [{"first": "C", "middle": ["M"], "last": "Chu", "suffix": ""}], "year": 2004, "venue": "Thorax", "volume": "59", "issn": "", "pages": "252--258", "other_ids": {}}, "BIBREF22": {"ref_id": "b22", "title": "Virological and serological analysis of a recent Middle East respiratory syndrome coronavirus infection case on a triple combination antiviral regimen", "authors": [{"first": "N", "middle": [], "last": "Spanakis", "suffix": ""}, {"first": "S", "middle": [], "last": "Tsiodras", "suffix": ""}, {"first": "B", "middle": ["L"], "last": "Haagmans", "suffix": ""}], "year": 2014, "venue": "Int J Antimicrob Agents", "volume": "44", "issn": "", "pages": "528--560", "other_ids": {}}, "BIBREF23": {"ref_id": "b23", "title": "Comparative and kinetic analysis of viral shedding and immunological responses in MERS patients representing a broad spectrum of disease severity", "authors": [{"first": "C-K", "middle": [], "last": "Min", "suffix": ""}, {"first": "S", "middle": [], "last": "Cheon", "suffix": ""}, {"first": "N-Y", "middle": [], "last": "Ha", "suffix": ""}], "year": 2016, "venue": "Sci Rep", "volume": "6", "issn": "", "pages": "", "other_ids": {}}, "BIBREF24": {"ref_id": "b24", "title": "Pulmonary Deposition and Clearance of Aerosolized Interferon", "authors": [{"first": "Philip", "middle": ["R"], "last": "Wyde", "suffix": ""}, {"first": "Samuel", "middle": ["Z"], "last": "Wilson", "suffix": ""}, {"first": "Michael", "middle": ["J"], "last": "Kramer", "suffix": ""}], "year": null, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}}, "ref_entries": {"FIGREF0": {"text": "......................................................................................................................................................... 6 .......................................................................................................................................................... 9 ............................................................................................................................................................ 10 ................................................................................................................................................ 13 1 ................................................................................................................................................... 15 2 ................................................................................................................... 16 2.1 ...................................................................................................................................... 16 2.2 ...................................................................................................................................... 17 2.3 .......................................................................................................................... 18 2.3.1 ............................................................................................................ 18 2.3.2 ............................................................................................................ 19 3 ............................................................................................................................................... 20 4 ............................................................................................................................... 21 4.1 .............................................................................................................................. 21 4.2 ...................................................................................................................................... 22 4.2.1 ........................................................................................................................ 22 4.2.2 ........................................................................................................................ 23 5 ....................................................................................................................................... 23 5.1 .......................................................................................................................... 23 5.2 .......................................................................................................................... 24 5.3 .......................................................................................................................... 24 5.4 .............................................................................................................. 24 5.4.1 ........................................................................................................ 25 5.4.2 .................................................................................... 25 6 ................................................................................................................................................... 26 6.1 ...................................................................................................................................... 26 6.1.1 ................................................................................................................................ 26 6.1.2 ........................................................................................................ 26 6.1.3 ........................................................................................................................ 26 6.1.4 ........................................................................................................................27 6.1.5 ................................................................................................................ 27 6.1.6 ........................................................................................................................ 27 6.2 ......................................................................................................................", "latex": null, "type": "figure"}, "FIGREF2": {"text": "(percentage) or median (interquartile range) is summarized as appropriate. Abbreviation: ICU = intensive care unit; HFNC = high-flow nasal oxygen therapy; IMV = intensive mechanical ventilation; ECMO = extracorporeal membrane oxygenation; TTCI = time to clinical improvement. Clinical improvement (the event) was defined as a decline of two categories on the modified seven-category ordinal scale of clinical status, or hospital discharge.", "latex": null, "type": "figure"}, "TABREF0": {"text": "27 12 ........................................................................................................................... 52 12.1 .................................................................................................................................. 52 12.2 .......................................................................................................................... 13 12.3 .............................................................................................................................. 13 12.3.1 ............................................................ 13 12.3.2 .................................................................................................... 14 12.4 ...................................................................................................................... 14 12.4.1 .................................................................... 54 13 ............................................................................................................................... 54 13.1 .................................................................................................................. 54 13.2 .............................................................................................................................. 5413.3 ...................................................................................................................................... 54 13.4 .................................................................................................................. 15 14 ........................................................................................................................................... 15 15 ................................................................................................................................................... 15 .......................................................................................................................................................... 57", "latex": null, "type": "table"}, "TABREF1": {"text": "............................................................................................................................................. 6 ............................................................................................................................................. 9", "latex": null, "type": "table"}, "TABREF2": {"text": ".. 15 2 ......................................................................................................... 16 2.1 ........................................................................................................................... 16 2.2 ................................................................................................................ 17 2.2.1 .................................................................................................. 17 ................................................................................................. 17 .................................................................................................. 17 ............................................. 17 1. .......................................... 17 \" \" .............................................. 19 \u03b12b .............................................................................. 19 ............................................. 20 \u03b12b ................................... 20 .................................................................................................. 20 3 .................................................................................................................................. 20 4 .................................................................................................................... 20 4.1 ................................................................................................................... 20 4.2 ........................................................................................................................... 22 4.2.1 ............................................................................................................. 22 4.2.2 ............................................................................................................. 23 5 ........................................................................................................................... 23 5.1 ................................................................................................................ 23 5.2 ................................................................................................................ 24 5.3 ................................................................................................................ 24 5.4 ..................................................................................................... 24 5.4.1 ............................................................................................... 24 ............................................................................. 25 6 ...................................................................................................................................... 26 6.1 ........................................................................................................................... 26 6.1.1 ..................................................................................................................... 26 6.1.2 ............................................................................................... 26 6.1.3 ............................................................................................................. 26 6.1.4 ............................................................................................................. 27 6.1.5 ...................................................................................................... 27 ............................................................................................................. 27 6.2 ............................................................................................................ 27 7 ....................................................................................................................... 27 7.1 ................................................................................................................ 27 7.1.1 ...................................................................................................... 27 7.1.2 ............................................................................................... 28 7.2 ............................................................................................................ 28 7.2.1 .................................................................................................. 28 .................................................................................................. 28 ........................................................................................ 28 7.2.4 ............................................................................................................. 29 7.2.5 .................................................................................................. 29 7.3 ....................................................................................................................... 29 7.3.1 ..................................................................................................................... 29 .......................................................................................................... 30 ..................................................................................................................... 31 7.3.4 ...................................................................................................... 31 7.3.5 ...................................................................................................... 32 7.3.6 .......................................................................................................... 33 7.4 ..................................................................................................... 37 7.4.1 ............................................................................. 37 7.5 ....................................................................................................... 1 7.6 ....................................................................................................... 1 7.7 .................................................................................... 1 8 .................................................................................................................................... 1 8.1 .......................................................................................................... 1 8.1.1 AE ........................................................................................ 2 8.1.2 SAE ............................................................................... 2 8.1.3 UP ..................................................................................... 2 8.2 ..................................................................................................................... 2 8.2.1 ........................................................................................................ 2 8.2.2 ................................................................................................. 3 8.2.3 .......................................................................................... 3 8.3 .................................................................................... 4 8.4 ............................................................................................................................. 5 8.4.1 ........................................................................................................ 5 8.4.2 ................................................................................................. 5 8.4.3 SUSAR ................................................................... 7 8.5 ..................................................................................................................... 8 8.6 ......................................................................................................................... 8 9 .................................................................................................................................... 9 9.1 .................................................................................................................................... 9 9.2 ................................................................................................................................ 9 9.3 ................................................................................................................................ 9 9.4 ............................................................................................................................. 9 9.5 ................................................................................................................... 10 9.5.1 ............................................................................................................. 10 9.5.2 ............................................................................................... 10 9.5.3 ...................................................................................................... 10 9.5.4 ............................................................................................................. 10 9.5.5 .......................................................................................................... 11 10 ..................................................................................................... 11 11 .................................................................................................................... 11 11.1. ........................................................................................................................ 11 11.2. ............................................................................................................................ 11 11.3. ................................................................................................................................... 11 11.4. ................................................................................................................. 12 11.5. ..................................................................................................................... 12 12 ................................................................................................................ 12 12.1 ....................................................................................................................... 12 12.2 ................................................................................................................ 13 12.3 ................................................................................................................... 13 12.3.1 ....................................................... 13 12.3.2 ........................................................................................... 14 12.4 ............................................................................................................ 14 12.4.1 .............................................................. 14 13 .................................................................................................................... 14 13.1 ........................................................................................................ 14 13.2 ................................................................................................................... 15 13.3 ........................................................................................................................... 15 13.4 ........................................................................................................ 15 14 ............................................................................................................................... 15 15 ...................................................................................................................................... 15 .......................................................................................................... 18 ........................................................................................................................................... 32 ........................................................................................................................................... 35 ............................................................................................................................................... 36 .................................................................................................................................... 39 2 ...................................................................................................................................... 39 2 ......................................................................................................... 41 2.1 ........................................................................................................................... 41 2.2 ................................................................................................................ 42 2.2.1 .................................................................................................. 42 .................................................................................................. 44 3 .................................................................................................................................. 44 4 .................................................................................................................... 45 4.1 ................................................................................................................... 45 4.2 ........................................................................................................................... 46 4.2.1 ............................................................................................................. 46 ............................................................................................................. 46 5 ........................................................................................................................... 47 5.1 ................................................................................................................ 47 5.2 ................................................................................................................ 47 5.3 ................................................................................................................ 48 5.4 ..................................................................................................... 48 5.4.1 ............................................................................................... 48 5.4.2 ............................................................................. 49 6 ...................................................................................................................................... 49 6.1 ........................................................................................................................... 49 6.1.1 ..................................................................................................................... 49 6.1.2 ............................................................................................... 50 6.1.3 ............................................................................................................. 50 6.1.4 ............................................................................................................. 50 6.1.5 ...................................................................................................... 50 6.1.6 ............................................................................................................. 506.2 ............................................................................................................ 50 7 ....................................................................................................................... 51 7.1 ................................................................................................................ 51 7.1.1 ...................................................................................................... 51 7.1.2 ............................................................................................... 51 7.2 ............................................................................................................ 51 7.2.1 .................................................................................................. 51 7.2.2 .................................................................................................. 51 7.2.4 ........................................................................................ 52 7.2.4 ............................................................................................................. 52 7.2.5 .................................................................................................. 52 7.3 ....................................................................................................................... 52 7.3.1 ..................................................................................................................... 52 7.3.2 .......................................................................................................... 53 7.3.3 ..................................................................................................................... 547.3.4 ...................................................................................................... 55 7.3.5 ...................................................................................................... 55 7.3.6 .......................................................................................................... 56 7.4 ..................................................................................................... 60 7.4.1 ............................................................................. 60 7.5 ..................................................................................................... 63 7.6 ..................................................................................................... 63 7.7 .................................................................................. 63 8 .................................................................................................................................. 63 8.1 ........................................................................................................ 63 8.1.1 AE ...................................................................................... 64 8.1.2 SAE ............................................................................. 64 8.1.3 UP ................................................................................... 64 8.2 ................................................................................................................... 64 8.2.1 ...................................................................................................... 64 8.2.2 ............................................................................................... 65 8.2.3 ........................................................................................ 65 8.3 .................................................................................. 66 8.4 ........................................................................................................................... 67 8.4.1 ...................................................................................................... 67 ............................................................................................... 67 SUSAR ................................................................. 69 8.5 ................................................................................................................... 70 8.6 ....................................................................................................................... 70 9.1 .................................................................................................................................. 71 9.2 .............................................................................................................................. 71 9.3 .............................................................................................................................. 71 9.4 ............................................................................................................................... 71 9.5 ................................................................................................................... 72 9.5.1 ............................................................................................................. 72 ............................................................................................... 72 ...................................................................................................... 72 ............................................................................................................. 72 .......................................................................................................... 72 10 ..................................................................................................... 73 11 .................................................................................................................... 73 11.1. ........................................................................................................................ 73 11.2. ............................................................................................................................ 73 11.3. ................................................................................................................................... 73 11.4. ................................................................................................................. 74 11.5. ..................................................................................................................... 74 12 ................................................................................................................ 74 12.1 ....................................................................................................................... 74 12.2 ................................................................................................................ 74 12.3 ................................................................................................................... 75 12.3.1 ....................................................... 75 12.3.2 ........................................................................................... 75 12.4 ............................................................................................................ 76 12.4.1 .............................................................. 76 13.1 ........................................................................................................ 76 13.2 ................................................................................................................... 76 13.3 ........................................................................................................................... 77 13.4 ........................................................................................................ 77 14 ............................................................................................................................... 77 15 ...................................................................................................................................... 77", "latex": null, "type": "table"}, "TABREF3": {"text": "Classification of Adverse Events using the NIH Common Terminology Criteria for", "latex": null, "type": "table"}, "TABREF4": {"text": "Summary of Adverse Events by severity.", "latex": null, "type": "table", "html": "<html><body><table><tr><td>Event </td><td>Lopinavir/ritonavir (n=XX) </td></tr><tr><td>Any Grade xx (xx.x) </td><td>Grade 3 or 4 xx (xx.x) </td></tr><tr><td>Any adverse event, n (%) </td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>Adverse Event 1 </td><td>xx (xx.x) xx (xx.x) </td><td>xx (xx.x) xx (xx.x) xx (xx.x) </td></tr><tr><td>Adverse Event 2 </td><td>\u00a0</td></tr><tr><td>xx (xx.x) </td></tr><tr><td>\u2026 </td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>Serious adverse event </td><td>xx (xx.x) xx (xx.x) </td><td>xx (xx.x) xx (xx.x) xx (xx.x) </td></tr><tr><td>Serious Adverse Event 1 </td><td>\u00a0</td></tr><tr><td>xx (xx.x) </td></tr><tr><td>Serious Adverse Event 2 </td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>\u2026 </td><td>xx (xx.x) </td><td>xx (xx.x) </td></tr></table></body></html>"}, "TABREF5": {"text": "Outcomes in the intention-to-treat population.", "latex": null, "type": "table", "html": "<html><body><table><tr><td>Variable </td><td>Intervention Group (N=XX) xx (xx, xx) xx (xx.x) xx (xx.x) </td><td>Control (N=XX) xx (xx, xx) xx (xx.x) xx (xx.x) xx (xx.x) </td><td>Differencec xx (xx, xx)\u2020 xx (xx, xx) xx (xx, xx) xx (xx, xx) xx (xx, xx) </td></tr><tr><td>TTCI </td></tr><tr><td>Day 28 mortality, n (%) </td></tr><tr><td>Early (\u013012 days of symptom onset) </td><td>\u00a0</td></tr><tr><td>Late (&gt; 12 days of symptom onset) </td><td>xx (xx.x) </td><td>\u00a0</td></tr><tr><td>Clinical improvement rates </td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>Day 7, n (%) </td><td>xx (xx.x) xx (xx.x) xx (xx.x) xx (xx, xx) xx (xx, xx) xx (xx, xx) xx (xx, xx) xx (xx, xx) xx (xx, xx) </td><td>xx (xx.x) xx (xx.x) xx (xx.x) xx (xx, xx) xx (xx, xx) xx (xx, xx) xx (xx, xx) xx (xx, xx) xx (xx, xx) xx (xx, xx) </td><td>xx (xx, xx) xx (xx, xx) xx (xx, xx) xx (xx, xx) xx (xx, xx) xx (xx, xx) xx (xx, xx) xx (xx, xx) xx (xx, xx) xx (xx, xx) xx (xx, xx) </td></tr><tr><td>Day 14, n (%) </td></tr><tr><td>Day 28, n (%) </td></tr><tr><td>ICU length of stay (days) </td></tr><tr><td>ICU length of stay of survivors (days) </td></tr><tr><td>ICU length of stay of non-survivors (days) </td></tr><tr><td>IMV duration (days) </td></tr><tr><td>Length of oxygen support (days) </td></tr><tr><td>Hospital length of stay (days) </td><td>\u00a0</td></tr><tr><td>Days from randomization to discharge (days) </td><td>xx (xx, xx) xx (xx, xx) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) </td><td>\u00a0</td></tr><tr><td>Days from randomization to death (days) Seven-category scale at day 7 </td><td>xx (xx, xx) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) </td><td>\u00a0</td></tr><tr><td>1 Not hospitalized, and resume normal activities, n (%) </td><td>\u00a0</td></tr><tr><td>2 Not hospitalized, but unable to resume normal activities, n (%) </td><td>\u00a0</td></tr><tr><td>3 Hospitalization, not requiring supplemental oxygen, n (%) </td><td>\u00a0</td></tr><tr><td>4 Hospitalization, requiring supplemental oxygen, n (%) </td><td>\u00a0</td></tr><tr><td>5 Hospitalization, requiring HFNC and/or non-IMV, n (%) </td><td>\u00a0</td></tr><tr><td>6 Hospitalization, requiring ECMO and/or IMV, n (%) </td><td>\u00a0</td></tr><tr><td>7 Death, n (%) Seven-category scale at day 14 </td><td>\u00a0</td></tr><tr><td>1 Not hospitalized, and resume normal activities, n (%) </td><td>\u00a0</td></tr><tr><td>2 Not hospitalized, but unable to resume normal activities, n (%) </td><td>\u00a0</td></tr><tr><td>3 Hospitalization, not requiring supplemental oxygen, n (%) </td><td>\u00a0</td></tr><tr><td>4 Hospitalization, requiring supplemental oxygen, n (%) </td><td>\u00a0</td></tr><tr><td>5 Hospitalization, requiring HFNC and/or non-IMV, n (%) </td><td>\u00a0</td></tr><tr><td>6 Hospitalization, requiring ECMO and/or IMV, n (%) </td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>7 Death, n (%) </td><td>xx (xx.x) Note. Number (percentage) or median (interquartile range) is summarized as appropriate. Abbreviation: ICU = </td></tr></table></body></html>"}, "TABREF6": {"text": "Outcomes in the modified intention-to-treat population.", "latex": null, "type": "table", "html": "<html><body><table><tr><td>Variable </td><td>Intervention Group (N=XX) xx (xx, xx) xx (xx.x) xx (xx.x) </td><td>Control (N=XX) xx (xx, xx) xx (xx.x) xx (xx.x) xx (xx.x) </td><td>Differencec xx (xx, xx)\u2020 xx (xx, xx) xx (xx, xx) xx (xx, xx) xx (xx, xx) </td></tr><tr><td>TTCI </td></tr><tr><td>Day 28 mortality, n (%) </td></tr><tr><td>Early (\u013012 days of symptom onset) </td><td>\u00a0</td></tr><tr><td>Late (&gt; 12 days of symptom onset) </td><td>xx (xx.x) </td></tr><tr><td>Clinical improvement rates </td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>Day 7, n (%) </td><td>xx (xx.x) xx (xx.x) xx (xx.x) xx (xx, xx) xx (xx, xx) xx (xx, xx) xx (xx, xx) xx (xx, xx) xx (xx, xx) </td><td>xx (xx.x) xx (xx.x) xx (xx.x) xx (xx, xx) xx (xx, xx) xx (xx, xx) xx (xx, xx) xx (xx, xx) xx (xx, xx) xx (xx, xx) </td><td>xx (xx, xx) xx (xx, xx) xx (xx, xx) xx (xx, xx) xx (xx, xx) xx (xx, xx) xx (xx, xx) xx (xx, xx) xx (xx, xx) xx (xx, xx) xx (xx, xx) </td></tr><tr><td>Day 14, n (%) </td></tr><tr><td>Day 28, n (%) </td></tr><tr><td>ICU length of stay (days) </td></tr><tr><td>ICU length of stay of survivors (days) </td></tr><tr><td>ICU length of stay of non-survivors (days) </td></tr><tr><td>IMV duration (days) </td></tr><tr><td>Length of oxygen support (days) </td></tr><tr><td>Hospital length of stay (days) </td><td>\u00a0</td></tr><tr><td>Days from randomization to discharge (days) </td><td>xx (xx, xx) xx (xx, xx) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) </td><td>\u00a0</td></tr><tr><td>Days from randomization to death (days) Seven-category scale at day 7 </td><td>xx (xx, xx) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) </td><td>\u00a0</td></tr><tr><td>1 Not hospitalized, and resume normal activities, n (%) </td><td>\u00a0</td></tr><tr><td>2 Not hospitalized, but unable to resume normal activities, n (%) </td><td>\u00a0</td></tr><tr><td>3 Hospitalization, not requiring supplemental oxygen, n (%) </td><td>\u00a0</td></tr><tr><td>4 Hospitalization, requiring supplemental oxygen, n (%) </td><td>\u00a0</td></tr><tr><td>5 Hospitalization, requiring HFNC and/or non-IMV, n (%) </td><td>\u00a0</td></tr><tr><td>6 Hospitalization, requiring ECMO and/or IMV, n (%) </td><td>\u00a0</td></tr><tr><td>7 Death, n (%) Seven-category scale at day 14 </td><td>\u00a0</td></tr><tr><td>1 Not hospitalized, and resume normal activities, n (%) </td><td>\u00a0</td></tr><tr><td>2 Not hospitalized, but unable to resume normal activities, n (%) </td><td>\u00a0</td></tr><tr><td>3 Hospitalization, not requiring supplemental oxygen, n (%) </td><td>\u00a0</td></tr><tr><td>4 Hospitalization, requiring supplemental oxygen, n (%) </td><td>\u00a0</td></tr><tr><td>5 Hospitalization, requiring HFNC and/or non-IMV, n (%) </td><td>\u00a0</td></tr><tr><td>6 Hospitalization, requiring ECMO and/or IMV, n (%) </td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>7 Death, n (%) </td><td>xx (xx.x) </td></tr></table></body></html>"}, "TABREF7": {"text": "Classification of Adverse Events using the NIH Common Terminology Criteria for", "latex": null, "type": "table"}, "TABREF8": {"text": "Summary of Adverse Events by severity.", "latex": null, "type": "table", "html": "<html><body><table><tr><td>Event </td><td>Lopinavir/ritonavir (n=XX) </td></tr><tr><td>Any Grade xx (xx.x) </td><td>Grade 3 or 4 xx (xx.x) </td></tr><tr><td>Any adverse event, n (%) </td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>Adverse Event 1 </td><td>xx (xx.x) xx (xx.x) </td><td>xx (xx.x) xx (xx.x) xx (xx.x) </td></tr><tr><td>Adverse Event 2 </td><td>\u00a0</td></tr><tr><td>xx (xx.x) </td></tr><tr><td>\u2026 </td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>Serious adverse event </td><td>xx (xx.x) xx (xx.x) </td><td>xx (xx.x) xx (xx.x) xx (xx.x) </td></tr><tr><td>Serious Adverse Event 1 </td><td>\u00a0</td></tr><tr><td>xx (xx.x) </td></tr><tr><td>Serious Adverse Event 2 </td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>\u2026 </td><td>xx (xx.x) </td><td>xx (xx.x) </td></tr></table></body></html>"}, "TABREF9": {"text": "Summary of Protocol Violations.", "latex": null, "type": "table", "html": "<html><body><table><tr><td>Characteristics </td><td>Intervention Group (N=XX) xx (xx.x) xx (xx.x) </td><td>SOC Group (N=XX) xx (xx.x) xx (xx.x) xx (xx.x) </td></tr><tr><td>Protocol Violations </td></tr><tr><td> xxxxx </td><td>\u00a0</td></tr><tr><td> xxxxx </td><td>xx (xx.x) </td><td>\u00a0</td></tr><tr><td>Reasons for protocol violations </td><td>\u00a0</td><td>\u00a0</td></tr><tr><td> xxxxx </td><td>xx (xx.x) xx (xx.x) </td><td>xx (xx.x) xx (xx.x) </td></tr><tr><td> xxxxx </td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>Any consequences </td><td>\u00a0</td><td>\u00a0</td></tr><tr><td> Yes </td><td>xx (xx.x) xx (xx.x) </td><td>xx (xx.x) xx (xx.x) </td></tr><tr><td>\u00a0</td><td>\u00a0</td><td> No </td></tr></table></body></html>"}, "TABREF10": {"text": "Outcomes in the intention-to-treat population.", "latex": null, "type": "table", "html": "<html><body><table><tr><td>Variable </td><td>Intervention Group (N=XX) xx (xx, xx) xx (xx.x) xx (xx.x) </td><td>Control (N=XX) xx (xx, xx) xx (xx.x) xx (xx.x) xx (xx.x) </td><td>Differencec xx (xx, xx)\u2020 xx (xx, xx) xx (xx, xx) xx (xx, xx) xx (xx, xx) </td></tr><tr><td>TTCI </td></tr><tr><td>Day 28 mortality, n (%) </td></tr><tr><td>Early (\u013012 days of symptom onset) </td><td>\u00a0</td></tr><tr><td>Late (&gt; 12 days of symptom onset) </td><td>xx (xx.x) </td><td>\u00a0</td></tr><tr><td>Clinical improvement rates </td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>Day 7, n (%) </td><td>xx (xx.x) xx (xx.x) xx (xx.x) xx (xx, xx) xx (xx, xx) xx (xx, xx) xx (xx, xx) xx (xx, xx) xx (xx, xx) </td><td>xx (xx.x) xx (xx.x) xx (xx.x) xx (xx, xx) xx (xx, xx) xx (xx, xx) xx (xx, xx) xx (xx, xx) xx (xx, xx) xx (xx, xx) </td><td>xx (xx, xx) xx (xx, xx) xx (xx, xx) xx (xx, xx) xx (xx, xx) xx (xx, xx) xx (xx, xx) xx (xx, xx) xx (xx, xx) xx (xx, xx) xx (xx, xx) </td></tr><tr><td>Day 14, n (%) </td></tr><tr><td>Day 28, n (%) </td></tr><tr><td>ICU length of stay (days) </td></tr><tr><td>ICU length of stay of survivors (days) </td></tr><tr><td>ICU length of stay of non-survivors (days) </td></tr><tr><td>IMV duration (days) </td></tr><tr><td>Length of oxygen support (days) </td></tr><tr><td>Hospital length of stay (days) </td><td>\u00a0</td></tr><tr><td>Days from randomization to discharge (days) </td><td>xx (xx, xx) xx (xx, xx) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) </td><td>\u00a0</td></tr><tr><td>Days from randomization to death (days) Seven-category scale at day 7 </td><td>xx (xx, xx) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) </td><td>\u00a0</td></tr><tr><td>1 Not hospitalized, and resume normal activities, n (%) </td><td>\u00a0</td></tr><tr><td>2 Not hospitalized, but unable to resume normal activities, n (%) </td><td>\u00a0</td></tr><tr><td>3 Hospitalization, not requiring supplemental oxygen, n (%) </td><td>\u00a0</td></tr><tr><td>4 Hospitalization, requiring supplemental oxygen, n (%) </td><td>\u00a0</td></tr><tr><td>5 Hospitalization, requiring HFNC and/or non-IMV, n (%) </td><td>\u00a0</td></tr><tr><td>6 Hospitalization, requiring ECMO and/or IMV, n (%) </td><td>\u00a0</td></tr><tr><td>7 Death, n (%) Seven-category scale at day 14 </td><td>\u00a0</td></tr><tr><td>1 Not hospitalized, and resume normal activities, n (%) </td><td>\u00a0</td></tr><tr><td>2 Not hospitalized, but unable to resume normal activities, n (%) </td><td>\u00a0</td></tr><tr><td>3 Hospitalization, not requiring supplemental oxygen, n (%) </td><td>\u00a0</td></tr><tr><td>4 Hospitalization, requiring supplemental oxygen, n (%) </td><td>\u00a0</td></tr><tr><td>5 Hospitalization, requiring HFNC and/or non-IMV, n (%) </td><td>\u00a0</td></tr><tr><td>6 Hospitalization, requiring ECMO and/or IMV, n (%) </td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>7 Death, n (%) </td><td>xx (xx.x) Note. Number (percentage) or median (interquartile range) is summarized as appropriate. Abbreviation: ICU = </td></tr></table></body></html>"}, "TABREF11": {"text": "Outcomes in the modified intention-to-treat population. Number (percentage) or median (interquartile range) is summarized as appropriate. Abbreviation: ICU = intensive care unit; HFNC = high-flow nasal oxygen therapy; IMV = intensive mechanical ventilation; ECMO = extracorporeal membrane oxygenation; TTCI = time to clinical improvement. Clinical improvement (the event) was defined as a decline of two categories on the modified seven-category ordinal scale of clinical status, or hospital discharge.", "latex": null, "type": "table"}, "TABREF12": {"text": "Classification of Adverse Events using the NIH Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0. Prolonged (e.g., not rapidly responsive to symptomatic medication and/or brief interruption of infusion); recurrence of symptoms following initial improvement; hospitalization indicated for clinical sequelae (e.g., renal", "latex": null, "type": "table"}, "TABREF13": {"text": "Life-threatening consequences, threats of harm to self or others;", "latex": null, "type": "table"}, "TABREF14": {"text": "Summary of Protocol Violations.", "latex": null, "type": "table", "html": "<html><body><table><tr><td>Characteristics </td><td>Intervention Group (N=XX) xx (xx.x) xx (xx.x) </td><td>SOC Group (N=XX) xx (xx.x) xx (xx.x) xx (xx.x) </td></tr><tr><td>Protocol Violations </td></tr><tr><td> xxxxx </td><td>\u00a0</td></tr><tr><td> xxxxx </td><td>xx (xx.x) </td><td>\u00a0</td></tr><tr><td>Reasons for protocol violations </td><td>\u00a0</td><td>\u00a0</td></tr><tr><td> xxxxx </td><td>xx (xx.x) xx (xx.x) </td><td>xx (xx.x) xx (xx.x) </td></tr><tr><td> xxxxx </td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>Any consequences </td><td>\u00a0</td><td>\u00a0</td></tr><tr><td> Yes </td><td>xx (xx.x) xx (xx.x) </td><td>xx (xx.x) xx (xx.x) </td></tr><tr><td>\u00a0</td><td>\u00a0</td><td> No </td></tr></table></body></html>"}, "TABREF15": {"text": "Summary of Adverse Events by severity.", "latex": null, "type": "table", "html": "<html><body><table><tr><td>Event </td><td>Lopinavir/ritonavir (n=XX) </td></tr><tr><td>Any Grade xx (xx.x) </td><td>Grade 3 or 4 xx (xx.x) </td></tr><tr><td>Any adverse event, n (%) </td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>Adverse Event 1 </td><td>xx (xx.x) xx (xx.x) </td><td>xx (xx.x) xx (xx.x) xx (xx.x) </td></tr><tr><td>Adverse Event 2 </td><td>\u00a0</td></tr><tr><td>xx (xx.x) </td></tr><tr><td>\u2026 </td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>Serious adverse event </td><td>xx (xx.x) xx (xx.x) </td><td>xx (xx.x) xx (xx.x) xx (xx.x) </td></tr><tr><td>Serious Adverse Event 1 </td><td>\u00a0</td></tr><tr><td>xx (xx.x) </td></tr><tr><td>Serious Adverse Event 2 </td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>\u2026 </td><td>xx (xx.x) </td><td>xx (xx.x) </td></tr></table></body></html>"}}, "back_matter": [{"text": "Note. Numbers in parenthesis correspond to interquartile range observed value for continuous variables and to percentages for indicator variables as appropriate. Abbreviation: NEWS2 = National Early Warning Score 2; HFNC = high-flow nasal cannula for oxygen therapy; IMV = invasive mechanical ventilation; ECMO = extracorporeal membrane oxygenation; SD = standard deviation.", "cite_spans": [], "ref_spans": [], "section": "annex"}]}